

Natural history, trajectory, and management of mechanically ventilated COVID-19 patients in the United Kingdom

Supplementary Appendix

Brijesh V Patel*, Shlomi Haar, Rhodri Handslip, Teresa Mei-Ling Lee, Sunil Patel, J. Alex Harston, Feargus Hosking-Jervis, Donna Kelly, Barnaby Sanderson, Barbara Bogatta, Kate Tatham, Ingeborg Welters, Luigi Camporota, Anthony C Gordon, Matthieu Komorowski, David Antcliffe, and John R Prowle, Zudin Puthucheary, A. Aldo Faisal*; on behalf of the United Kingdom COVID-ICU National Service Evaluation.

***Clinical Science contact** – Dr Brijesh V Patel MD PhD. Clinical Senior Lecturer & Consultant in Intensive Care Medicine. Division of Anaesthetics, Pain Medicine & Intensive Care, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Department of Adult Intensive Care, The Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP

email: brijesh.patel@imperial.ac.uk

***Data Science contact** – Professor A. Aldo Faisal PhD. Professor of AI & Neuroscience. Dept. Of Computing & Dept. Of Bioengineering and Behaviour Analytics Lab, Data Science Institute and UKRI Centre for Doctoral Training in AI for Healthcare, Imperial College London, SW7 2AZ London, UK, and MRC London Institute for Medical Sciences, London W12 0NN UK

email: aldo.faisal@imperial.ac.uk

Table of Contents

COVID-ICU NATIONAL SERVICE EVALUATION CONSORTIUM MEMBERS	3
STROBE STATEMENT	4
DETAILED METHODS	7
TABLE S1 - INDIVIDUAL SITE CONTRIBUTIONS	10
TABLE S2 - VARIABLES INCLUDED IN LOGISTIC REGRESSION MODELS.....	11
TABLE S3 - DISTRIBUTION OF CO-MORBIDITIES WITH A) SEVERITY ON ADMISSION AND B) ICU OUTCOME ..	12
TABLE S4 - COMPARISON BETWEEN COVID-ICU AND ICNARC.....	13
TABLE S5 - THE APPLICATION, MEDIAN START DATE AND DURATION OF THE FIRST EPISODE OF INTERVENTIONS.....	14
TABLE S6 - CLINICAL AND PHYSIOLOGICAL CHARACTERISTICS, OUTCOMES AND INTERVENTIONS ACCORDING TO RESOLUTION OF HYPOXAEMIA OVER FIRST WEEK OF INVASIVE MECHANICAL VENTILATION.....	15
TABLE S7 - TIME SERIES MIXED MODEL ANOVA ACCORDING TO RESOLUTION OF HYPOXAEMIA OVER FIRST WEEK OF MECHANICAL VENTILATION.....	16
TABLE S8 - UNI- AND MULTI-VARIATE MODEL ANALYSIS OF FACTORS ASSOCIATED WITH PROGRESSION OF HYPOXAEMIA OVER THE FIRST WEEK OF INVASIVE MECHANICAL VENTILATION	17
TABLE S9 - CLINICAL AND PHYSIOLOGICAL CHARACTERISTICS, OUTCOMES AND INTERVENTIONS ACCORDING TO PRONE RESPONSIVENESS.....	18
TABLE S10 - TIME SERIES MIXED MODEL ANOVA ACCORDING TO PRONE RESPONSIVENESS.	19
TABLE S11 - UNI- AND MULTI-VARIATE MODEL ANALYSIS OF PRE-PRONING FACTORS ASSOCIATED PRONE RESPONSIVENESS.....	20
TABLE S12 - UNI- AND MULTI-VARIATE MODEL ANALYSIS OF POST-PRONING FACTORS ASSOCIATED PRONE RESPONSIVENESS.....	21
TABLE S13- CLINICAL AND PHYSIOLOGICAL CHARACTERISTICS, OUTCOMES AND INTERVENTIONS ACCORDING TO ICU OUTCOME.	22
TABLE S14 - TIME SERIES MIXED MODEL ANOVA ACCORDING TO ICU OUTCOME.....	23
TABLE S15- UNI- AND MULTI-VARIATE MODEL ANALYSIS OF FACTORS ASSOCIATED WITH ICU MORTALITY.	24
TABLE S16 - CARDIAC ARREST AND END OF LIFE DECISIONS	25
TABLE S17 - MISSING VALUES FOR EACH PARAMETER.....	26
FIGURE S1 – TIME-SERIES COMPARISON BETWEEN ADMISSION SEVERITY GROUPS	27
FIGURE S2 – SITE VARIATION OF APPLICATION OF INTERVENTIONS	28
FIGURE S3 – TIME SERIES COMPARISON BETWEEN OUTCOME GROUPS	29

UK COVID-ICU National Service Evaluation Consortium members

Study Committee: Brijesh V Patel, Shlomi Haar, Rhodri Handslip, David Antcliffe, Ingeborg Welters, Luigi Camporota, John Prowle, Zudin Puthucheary, and Aldo Faisal

Writing Committee: Brijesh V Patel, Shlomi Haar, David Antcliffe, Ingeborg Welters, Barnaby Sanderson, Luigi Camporota, John Prowle, Zudin Puthucheary, and Aldo Faisal

Data Science Team: Dr Brijesh Patel, Dr Rhodri Handslip, Feargus Hosking-Jervis, Dr Matthieu Komorowski; Dr Shlomi Haar, Professor Aldo Faisal

Site Contributions (*Site leads): **Aintree University Hospitals NHS Foundation Trust:** Emma Addie; Barbara Borgatta*; Roz Chisholm; Alexandra Crocokft; Anna Gilfedder; Peter Harding; Gladys Madzamba; Namratha Mathai; Maya Patel; Amie Reddy; Leanne Smith; Ian Turner-Bone; Lilian Wajero; Raegan Wignall; Laura Wilding. **Guys & St Thomas' NHS Foundation Trust:** Gill Arbane; Luigi Camporota*; Alison Dixon; Barnaby Sanderson*. **Imperial College Healthcare NHS Trust:** David Antcliffe*; Mariana Ferrari Barbosa; Carlos Gomez; Abdalla Kaware, Fady Tarek Khalil, Matthieu Komorowski*, Maie Templeton, Raja Bilal Zafar. **University Hospitals of Leicester NHS Trust:** Mrs Michelle Craner; Mrs Sarah Edwards: Neil Flint; Dr Graziella Isgro; Hakeem Yusuff*. **Liverpool University Hospitals NHS Foundation Trust:** Jaime Fernandez Roman; Oliver Hamilton; Brian Johnson; Emily Johnson; Maria Lopez Martinez; Suleman Mulla; David Shaw; Alicia Waite; Victoria Waugh; Ingeborg Welters*; Karen Williams. **Newcastle upon Tyne Hospitals NHS Foundation Trust:** Benjamin Evans; Lewis Gray; Sam Horne; Natalie Jones; Donna Kelly*; Rebecca Lawrence; Jennifer Partridge; Antonia Snell; Lucy Venyo; Thomas Walker. **Royal Brompton and Harefield NHS Foundation Trust:** Frank Barrett; Sebastian Cabero Alonso; Masoomeh Farazdaghi; Ben Garfield; Clara Hernandez Caballero; Stephane Ledot; Teresa Lee; James Leslie; Helen McGuire; Lorraine O'Connor; Maurizio Passariello; Brijesh Patel*; Sunil Patel; Alex Rosenberg; Jennifer Thomson; Dhulamini Wijeratne. **Royal Cornwall Hospitals NHS Trust:** Sarah Bean; Karen Burt; Rosanna Jury; Oliver Quick; Michael Spivey*; Josh Thorns. **Barts Health NHS Trust:** Sana Ali; Thomas Beazer; Matilda Boa; Rosemarie Burd; Zoe Burdon; J Burgess; Natalie Cameron; A Daou; Charles Fadipe; FAJ Freer; Gayle Fung; Lindsey Iles; Aaron Jones; Agne Jovaisaita; Gabriella Knight; Veda Kudva; J Lampard; Ruby Lightfoot; Nicholas Low; Caroline Olabisi; Osama Omrani; Rebecca Pease; John Prowle*; Zudin Puthucheary*; Johnathan Mak; Aamir Saiyed; Maria Salamanca; Gauri Saxena; W Stanley; Nida Tahir; Yize Wan; Anton Weatherhead. **Royal Papworth Hospital NHS Foundation Trust:** Linzi Dunham; Melissa Earwaker*; Amy Gladwell. **Royal Marsden Hospital NHS Foundation Trust:** Thomas Bemand; Ethel Black; Samantha Coulson; Arnold Dela Rosa; Shamen Jhanji; Ravishankar Rao Baikady; Kate Tatham; Zoszka Webb*. **South Tyneside and Sunderland NHS Foundation Trust:** Sarah Cornell; Anthony Rostron*; Fiona Wakinshaw; Lindsey Woods.

STROBE statement

Item	No	Recommendation	Page
			No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	1-4 4
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6-7
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (b) For matched studies, give matching criteria and number of exposed and unexposed	6 NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	6-7
Study size	10	Explain how the study size was arrived at	6

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses	6-7 6 7 NA NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram	8 8 Fig1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount)	8 NA 8-9
Outcome data	15*	Report numbers of outcome events or summary measures over time	8-11

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	8-11 NA NA
Other analyses	17	Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses	8-11

Discussion

Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-15
Generalisability	21	Discuss the generalisability (external validity) of the study results	15

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	3
---------	----	---------------------------------------------------------------------------------------------------------------------------------------------------------------	---

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

Detailed Methods

Study design: We performed a multicentre, observational cohort study in patients with SARS-CoV-2 infection who required mechanical ventilation for severe Covid-19 infection in the United Kingdom.

Exposure: Adult patients (aged ≥ 18 years) with laboratory confirmed SARS-CoV-2 infection who required mechanical ventilation in the United Kingdom between March 1st and August 31st 2020.

Ethical approval: Each site registered the protocol as a service evaluation, as approved by the United Kingdom's Health Research Authority. All patients lacked capacity, and the need for individual informed consent was waived for collection of data during routine care, with no breach of privacy or anonymity. The "Strengthening the Reporting of Observational Studies in Epidemiology" statement guidelines were applied (see supplementary appendix pages 4-5)¹.

Data collection and procedures:

We set up a data processing pipeline where only routine, anonymised data was collected with no change to clinical care. Patients were identified through daily review of paper or electronic medical records using a standardised case record form (CRF), with retrospective and prospective data collection permitted. Data was extracted from either electronic healthcare records (EHRs) or paper-based records. Sites were given the option to submit their EHRs either in a predetermined format set by the Covid-ICU own secure REDCap database form fields or as a raw dump of data in CSV file format, that was then record-by-record manually screened for data consistency. Paper-based ICU operations sites were able to enter the data directly by the site representative into our RedCAP Electronic Data Capture (RedCAP v10.0.10; Vanderbilt University, US, local version hosted by Imperial College servers in the UK).

Each site's representative was given a unique username and password for data entering-only access to the database to connect via an encrypted online connection. Confidentiality was protected through a de-identified study number. A range of ICUs were included including secondary and tertiary care organisations (Table S1). In brief, the CRF captured admission demographics, twice daily (8am and 8pm) respiratory physiology and blood gas results, daily ARDS interventions, daily Covid interventions, daily blood results and outcome status. Patients were categorized within 48 hours of invasive mechanical ventilation (IMV) based on their $\text{PaO}_2/\text{FIO}_2$ ratio into no ARDS, mild, moderate, and severe ARDS².

Resolution of hypoxaemia over first week of IMV. Hypoxaemia was categorised as per Berlin definition of ARDS². First week resolvers were defined by moving over the first week of mechanical ventilation to a less severe ARDS hypoxaemia category, and vice-versa for non-resolvers^{2,3}. In addition to the patients who resolved, also those who remained mild or got discharged were considered “resolvers” while those who deteriorate, remained moderate or severe, or died, were considered “non-resolvers”.

Responsiveness to prone position. We defined a positive prone responsiveness as a sustained increase in mean PaO₂/FiO₂ above 20kPa over 7 days, following the first PP episode.

Statistical analysis. Descriptive variables are expressed as percentage, or median and interquartile range (IQR), as appropriate. The distribution of each variable on each day in each outcome group was tested for normality using the Shapiro-Wilks test, and where necessary and appropriate, because of skewed distributions, continuous variables were log-transformed (e.g. FiO₂). Continuous variables were analysed with Mann Whitney U or Kruskall Wallis tests, as appropriate. Categorical variables were compared using Fisher's exact test or the Chi-square test for equal proportion, as appropriate. All statistical tests were 2-sided and $p \leq 0.05$ was considered statistically significant. For group-wise analysis, the outcome of the therapies was measured as categorical variables of “Mild or Moderate or Severe”, “Survival or Death”, “resolver or non-resolver”, and “prone responder or prone non-responder”. Hypoxaemia was categorised as per Berlin definition of ARDS². First week resolvers were defined by moving over the first week of mechanical ventilation to a less severe ARDS hypoxaemia category, and vice-versa for non-resolvers². We defined a positive prone responsiveness as a sustained increase in mean PaO₂/FiO₂ above 20kPa over 7 days, following the first PP episode. Analyses were carried out using Matlab (Mathworks Inc., Natick, MA).

Interventions periods. The incidence and duration of interventions as well as ventilation setting were analysed and reported to current strategies e.g. low tidal volume ventilation and ARDSNet PEEP tables. We defined an intervention period as a daily application of the intervention with a day of no intervention defining the end of the current period and the onset of the next period.

Logistic regression models. Multivariate logistic regression models were applied (with screening univariate, $p < 0.1$) to each outcome variable to test associations with independent variables. The full list of variables tested for inclusion in these models is shown in Table S2, but only variables with less

than 40% missingness were included in each outcome model. For all outcomes, only patients with more than 80% of the variables were included in the models. Accordingly, up to 20% of the data were missing and thus were imputed. Data were assumed to be missing at random (MAR) owing to the nature of different personnel at many different sites completing each data entry (missing value analysis is shown in Table S17). To enable interpretable and comparable odds ratios, all continuous variables were transformed to categorical by splitting them into quartiles. Accordingly, the odds ratio is the risk increase per quartile increase in the measurement. For age, the odds ratio is the risk increase per decade increase; for SOFA scores, the odds ratio is the risk increase per unit increase in the SOFA score; and for binary variables (e.g., gender, comorbidities) the odds ratio is the risk increase of being positive (e.g. being male, having comorbidity).

Statistical analysis of natural history and management. The association between the change over time of each independent variable and the outcome measures was tested in repeated measures ANOVA. For the survival and first week resuscitation outcome, repeated measure ANOVA was applied on the physiology variables over the first week of mechanical ventilation, while for the prone responder outcome, it was applied on the physiology variables over a week from the day before the first PP episode. The repeated measure ANOVA was applied separately to each physiology variable, and for each variable, only patients with more than 80% of the variable's measurements over that week were included in the model. Variables for which fewer than 30 patients had more than 80% of the measurements were not analysed.

References.

- 1 Elm E von, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies*. B World Health Organ 2007; 85: 867–72.
- 2 Acute Respiratory Distress Syndrome: The Berlin Definition. Jama 2012; 307: 2526–33.
- 3 Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. Jama 2016; 315: 788–800.

Table S1 - Individual site contributions

ICU site	Number	Proportion of total	Outcome (Mortality rate)	percentage transferred in
A	1	0.2%	0.0%	100.0%
B	18	2.9%	27.8%	5.6%
C	35	5.6%	31.4%	82.9%
D	49	7.9%	34.7%	79.6%
E	19	3.0%	26.3%	15.8%
F	36	5.8%	47.2%	44.4%
G	57	9.1%	59.6%	7.0%
H	34	5.5%	64.7%	0.0%
I	34	5.5%	29.4%	76.5%
J	3	0.5%	66.7%	0.0%
K	64	10.3%	51.6%	4.7%
L	54	8.7%	48.1%	3.7%
M	4	0.6%	75.0%	50.0%
N	9	1.4%	33.3%	77.8%
O	31	5.0%	35.5%	16.1%
P	2	0.3%	100.0%	0.0%
Q	173	27.8%	32.4%	12.1%
Total	623			

Table S2 - Variables included in logistic regression models

Age	
Gender	
BMI	
Weight	
Height	
Days since symptoms onset	
Hypertension	
Diabetes mellitus	
Prone initiation day	* only in the pre- post-prone models
Oxygen saturation	
pH	
PaCO ₂	
HCO ₃ ⁻	
Lactate	
Peak pressure	
PEEP	
Minute ventilation	
Dynamic Compliance	
Oxygenation Index	
Ventilatory Ratio	
Cumulative fluid balance	
Neutrophils	
Monocytes	
Eosinophils	
APTT	
PT	
Fibrinogen	
D-dimer	
BUN	
Sodium	
Potassium	
Alkaline Phosphatase	
ALT	
LDH	
Ferritin	
CRP	
Creatinine Kinase	
High sensitivity Troponin	
NT Pro BNP	
SOFA Respiratory	
SOFA Nervous	
SOFA Cardiovascular	
SOFA Liver	
SOFA Coagulation	
SOFA Kidneys	
SOFA score	

Table S3 - Distribution of co-morbidities with a) severity on admission and b) ICU outcome

Co-morbidity according to severity	ALL			MILD			MODERATE			SEVERE			P value
	Total N	N	%	Group N	N	%	Group N	N	%	Group N	N	%	
BMI>30 kg/m2	516	203	39.3	122	43	35.25	275	106	38.5	119	54	45.4	0.691
Myocardial infarction	563	16	2.8	127	5	3.94	289	7	2.4	147	4	2.7	0.734
Congestive Heart Failure	563	11	2.0	126	2	1.59	290	6	2.1	147	3	2.0	0.922
Peripheral vascular disease	564	9	1.6	127	1	0.79	290	6	2.1	147	2	1.4	0.585
CVA or TIA	564	16	2.8	127	3	2.36	290	9	3.1	147	4	2.7	0.886
Dementia	564	2	0.4	127	1	0.79	290	1	0.3	147	0	0.0	0.567
Hypertension	564	238	42.2	127	50	39.37	290	131	45.2	147	57	38.8	0.260
Pregnancy	356	1	0.3	69	0	0.00	180	1	0.6	107	0	0.0	0.617
COPD	565	41	7.3	127	10	7.87	291	24	8.2	147	7	4.8	0.400
Connective tissue disease	563	5	0.9	127	1	0.79	289	4	1.4	147	0	0.0	0.339
Peptic ulcer disease	563	8	1.4	127	1	0.79	290	5	1.7	146	2	1.4	0.733
Diabetes mellitus	564	171	30.3	127	45	35.43	290	92	31.7	147	34	23.1	0.102
Diabetes mellitus - end organ damage	559	18	3.2	125	5	4.00	288	10	3.5	146	3	2.1	0.655
Hemiplegia	355	2	0.6	68	1	1.47	180	1	0.6	107	0	0.0	0.567
Moderate to severe CKD	356	20	5.6	69	4	5.80	180	13	7.2	107	3	2.8	0.398
Solid tumour	565	24	4.2	127	7	5.51	291	10	3.4	147	7	4.8	0.639
Leukemia	356	7	2.0	69	1	1.45	180	6	3.3	107	0	0.0	0.152
Lymphoma	355	5	1.4	69	1	1.45	179	4	2.2	107	0	0.0	0.339
AIDS	564	5	0.9	127	3	2.36	290	2	0.7	147	0	0.0	0.114
Steroid use	355	14	3.9	69	3	4.35	179	10	5.6	107	1	0.9	0.207
Other Immunosuppression use	356	15	4.2	69	4	5.80	180	10	5.6	107	1	0.9	0.221
History of Deep Vein Thrombosis	353	7	2.0	68	4	5.88	178	2	1.1	107	1	0.9	0.103
History of Pulmonary Embolus	354	5	1.4	69	1	1.45	178	3	1.7	107	1	0.9	0.918

Co-morbidity according to outcome	Survivors			Non-Survivors			P value
	Group N	N	%	Group N	N	%	
BMI>30 kg/m2	315	133	42.22	201	70	34.83	0.017
Myocardial infarction	325	4	1.23	238	12	5.04	0.005
Congestive Heart Failure	325	2	0.62	238	9	3.78	0.006
Peripheral vascular disease	325	5	1.54	239	4	1.67	0.845
CVA or TIA	325	10	3.08	239	6	2.51	0.757
Dementia	325	1	0.31	239	1	0.42	0.801
Hypertension	325	128	39.38	239	110	46.03	0.048
Pregnancy	184	0	0.00	172	1	0.58	0.232
COPD	326	19	5.83	239	22	9.21	0.095
Connective tissue disease	325	1	0.31	238	4	1.68	0.077
Peptic ulcer disease	325	3	0.92	238	5	2.10	0.219
Diabetes mellitus	325	95	29.23	239	76	31.80	0.319
Diabetes mellitus - end organ damage	322	8	2.48	237	10	4.22	0.211
Hemiplegia	184	1	0.54	171	1	0.58	0.801
Moderate to severe CKD	184	8	4.35	172	12	6.98	0.083
Solid tumour	325	12	3.69	240	12	5.00	0.375
Leukemia	184	2	1.09	172	5	2.91	0.103
Lymphoma	184	1	0.54	171	4	2.34	0.077
AIDS	325	4	1.23	239	1	0.42	0.332
Steroid use	184	8	4.35	171	6	3.51	0.902
Other Immunosuppression use	184	7	3.80	172	8	4.65	0.336
History of Deep Vein Thrombosis	183	2	1.09	170	5	2.94	0.103
History of Pulmonary Embolus	183	2	1.09	171	3	1.75	0.393

Table S4 - Comparison between Covid-ICU and ICNARC

	Covid-19 undergoing IMV	
	COVID-ICU	ICNARC*
	N=623	N=7,702
Patient characteristics		
Age (years), median (IQR)	59.0 [51.0 66.0]	60 (51-67)
Sex, n (%)		
Male	474 (76.1%)	5,544 (72.0%)
Ethnicity, n (%)		
White	240 (38.5%)	4,653 (60.4%)
Asian	73 (11.7%)	1,256 (16.3%)
Black	115 (18.5%)	804 (10.4%)
Other	103 (16.5%)	693 (9.0%)
Not stated	91 (14.6%)	296 (3.8%)
BMI (kg/m ²), median (IQR)	28.1 [24.9 32.7]	28.3 (24.9-33.0)
BMI categories (kg/m ²), n (%)		
>30	203 (39.3%)	39.9%
Acute illness severity⁴		
P/F Ratio (kPa), ⁵ median (IQR)	18.4 [13.0 25.1]	15.0 (10.8-21.0)
P/F ratio categories (kPa) ⁵		
≤13.3kPa (≤100mmHg)	11.0 [9.6 12.1]	3,033 (40.4%)
13.3-26.7kPa (100-200mmHg)	18.7 [16.0 21.9]	3,530 (47.0%)
>26.7kPa (>200mmHg)	35.6 [30.0 42.4]	952 (12.7%)
Organ support^{8,9}		
<i>Renal support</i>		
Receipt, n (%)	206 (33.1%)	2,708 (35.2%)
Duration (calendar days), median (IQR)	8.0 [4.0 14.0]	8 (4-15)
Outcome		
<i>Critical care</i>		
Survived, n (%)	366 (58.7%)	4,018 (52.2%)
Died, n (%)	257 (41.3%)	3,684 (47.8%)
Duration of stay (calendar days)		
IMV, median (IQR)	13.0 [7.3 22.0]	13 (7-23)
Survived – median (IQR)	15.0 [8.0 28.0]	-
Died – median (IQR)	11.0 [7.0 16.3]	-
Critical care, median (IQR)	14.0 [8.0 23.0]	15.0 (8.0-27.0)
Survived – median (IQR)	17.0 [10.0 30.0]	22.0 (12.0-36.0)
Died – median (IQR)	11.0 [7.0 18.0]	10.0 (6.0-17.0)
* Richards-Belle, A., Orzechowska, I., Gould, D., Thomas, K., Doidge, J., Mouncey, P., Christian, M., Shankar-Hari, M., Harrison, D., Rowan, K., Banjo, Y., Borowczak, K., Cousins, T., Cummins, P., Dalemo, K., Darnell, R., Demissie, H., Drikite, L., Fleming, A., Frederiksen, D., Furnell, S., Hussein, A., Koelewijn, A., Matthews, T., Peters, S., Samuels, T., Saull, M. (2020). COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland Intensive Care Medicine https://dx.doi.org/10.1007/s00134-020-06267-0		

Table S5 - The application, median start date and duration of the first episode of interventions

	Start day of first intervention	Duration of first intervention	Number of periods
interventions	median [IQR]	median [IQR]	median [IQR]
Neuro-muscular blockade	1.0 [0.0 3.0]	4.0 [1.0 7.0]	1.0 [1.0 2.0]
Prone positioning	2.0 [0.5 5.0]	2.0 [1.0 4.0]	1.0 [1.0 2.0]
Inhaled nitric oxide	6.0 [3.0 9.0]	4.0 [2.0 7.3]	1.0 [1.0 1.0]
Inhaled prostacyclin	7.5 [3.0 15.0]	3.0 [1.0 7.0]	1.0 [1.0 1.0]
Tracheostomy	14.0 [9.0 18.0]	13.0 [6.0 20.0]	1.0 [1.0 1.0]
APRV	3.0 [0.5 6.0]	3.0 [2.0 5.0]	1.0 [1.0 1.0]
Bronchoscopy	10.0 [2.8 16.0]	1.0 [1.0 1.0]	1.0 [1.0 1.0]
Renal replacement therapy	3.0 [1.0 6.0]	5.5 [3.0 11.0]	1.0 [1.0 2.0]
Diuretics	1.0 [1.0 3.0]	3.0 [1.0 5.0]	2.0 [1.0 3.0]
Corticosteroids	5.0 [1.0 10.0]	4.0 [2.0 9.0]	1.0 [1.0 2.0]
Therapeutic heparin	9.0 [6.0 14.0]	5.0 [2.0 8.8]	1.0 [1.0 1.0]
Anti-Bacterial	0.0 [0.0 0.0]	6.0 [4.3 9.0]	1.0 [1.0 2.0]

Table S6 - Clinical and physiological characteristics, outcomes and interventions according to resolution of hypoxaemia over first week of invasive mechanical ventilation.

Clinical Characteristics		All	Trajectory between admission and day 7				
			Resolving		Non resolving		
label	units	Total N	median [IQR] / N (%)	N	median [IQR] / N (%)	N	median [IQR] / N (%) P Value
Male		623	474 (76.1%)	263	193 (73.4%)	360	281 (78.1%) 0.177
White		532	240 (45.1%)	212	94 (44.3%)	320	146 (45.6%) 0.223
Age	years	623	59.0 [51.0 66.0]	263	57.0 [47.0 64.0]	360	60.0 [54.0 67.0] 0.000
BMI	kg/m ²	516	28.1 [24.9 32.7]	219	28.0 [24.8 32.9]	297	28.1 [25.1 32.2] 0.696
Time since onset of symptoms	days	399	8.0 [6.0 12.0]	160	9.5 [6.5 14.0]	239	7.0 [6.0 11.0] 0.003
ICU length of stay	days	623	14.0 [8.0 23.0]	263	13.0 [7.0 20.0]	360	15.0 [9.0 26.0] 0.014
Length of mechanical ventilation	days	623	13.0 [7.3 22.0]	263	12.0 [6.0 19.0]	360	14.0 [8.0 24.0] 0.001
ICU Mortality	%	623	257 (41.3%)	263	43 (16.3%)	360	214 (59.4%) 0.000
Vent							
FiO ₂ (%)		618	60.0 [45.0 80.0]	259	60.0 [40.0 80.0]	359	60.0 [50.0 70.0] 0.275
PaO ₂ to FiO ₂ ratio		616	18.4 [13.0 25.1]	258	18.1 [11.7 27.5]	358	18.4 [14.6 24.0] 0.386
Tidal Volume (mls/IBW)	ml/Kg(IBW)	471	6.8 [6.0 7.8]	201	6.9 [6.1 7.8]	270	6.8 [6.0 7.7] 0.339
Respiratory rate	bpm	617	18.0 [16.0 22.0]	259	18.0 [16.0 22.0]	358	19.0 [16.0 22.0] 0.248
Minute ventilation	L/minute	596	8.5 [6.9 10.4]	251	8.4 [7.0 10.2]	345	8.5 [6.8 10.5] 0.599
Peak pressure	ml/Kg(RBW)	589	26.0 [23.0 30.0]	249	25.0 [22.0 29.0]	340	26.7 [24.0 30.0] 0.004
Plateau pressure	ml/kg(IBW)	78	25.5 [22.0 28.0]	27	24.0 [21.3 29.0]	51	26.0 [23.0 28.0] 0.402
PEEP	cmH ₂ O	593	10.0 [8.0 12.0]	253	10.0 [8.0 12.0]	340	10.0 [8.3 12.0] 0.007
Mean airway pressure	cmH ₂ O	384	16.0 [13.3 19.0]	173	15.5 [13.0 18.0]	211	16.0 [14.0 20.0] 0.032
Pressure support	cmH ₂ O	362	10.0 [6.0 14.0]	156	10.0 [5.0 12.5]	206	10.0 [8.0 14.0] 0.616
Dynamic Compliance	mls/cmH2O	555	31.4 [24.3 40.1]	238	32.5 [25.2 40.6]	317	30.3 [24.0 40.1] 0.270
Oxygenation Index		384	8.1 [5.1 12.6]	173	7.7 [4.6 13.1]	211	8.2 [5.4 11.9] 0.537
Ventilatory Ratio		261	1.8 [1.4 2.2]	102	1.8 [1.4 2.2]	159	1.8 [1.4 2.2] 0.550
ABG							
Oxygen saturation		508	95.0 [93.0 98.0]	220	96.0 [93.0 98.0]	288	95.0 [92.0 97.0] 0.057
pH		620	7.4 [7.3 7.4]	261	7.4 [7.3 7.4]	359	7.4 [7.3 7.4] 0.055
PaO ₂	kPa	620	10.7 [9.2 13.1]	261	10.4 [8.8 12.4]	359	10.9 [9.4 13.4] 0.022
PaCO ₂	kPa	412	6.2 [5.3 7.6]	164	6.2 [5.2 7.7]	248	6.3 [5.3 7.5] 0.713
Base excess		620	-0.3 [-2.6 2.2]	261	0.3 [-1.9 2.5]	359	-0.7 [-3.0 1.8] 0.002
HCO ₃ ⁻	mmol/L	619	24.5 [22.5 26.7]	261	25.0 [23.0 27.2]	358	24.0 [22.0 26.4] 0.000
Lactate	mmol/L	594	1.2 [1.0 1.6]	256	1.2 [1.0 1.6]	338	1.3 [1.0 1.6] 0.092
SOFA							
SOFA score		419	9.0 [7.0 11.0]	180	9.0 [7.0 11.0]	239	9.0 [7.0 11.0] 0.785
SOFA Respiratory		616	3.0 [3.0 3.0]	258	3.0 [2.0 4.0]	358	3.0 [3.0 3.0] 0.064
SOFA Nervous		498	2.5 [0.0 4.0]	214	1.5 [0.0 4.0]	284	3.0 [0.0 4.0] 0.761
SOFA Cardiovascular		569	3.0 [3.0 4.0]	238	3.0 [1.0 4.0]	331	3.0 [3.0 4.0] 0.004
SOFA Liver		579	0.0 [0.0 0.0]	248	0.0 [0.0 0.0]	331	0.0 [0.0 0.0] 0.945
SOFA Coagulation		609	0.0 [0.0 0.0]	253	0.0 [0.0 0.0]	356	0.0 [0.0 0.0] 0.249
SOFA Kidneys		619	0.0 [0.0 1.0]	260	0.0 [0.0 1.0]	359	0.0 [0.0 1.0] 0.479
FBC							
Haemoglobin	g/dL	609	114.0 [93.0 128.0]	253	113.0 [91.0 126.3]	356	115.0 [94.5 130.0] 0.197
Haematocrit		302	0.4 [0.3 0.4]	122	0.4 [0.3 0.4]	180	0.4 [0.3 0.4] 0.062
White blood cell count	x10 ⁹ /L	609	9.6 [7.0 13.1]	253	9.6 [6.9 12.9]	356	9.5 [7.1 13.5] 0.989
Neutrophils	x10 ⁹ /L	608	8.1 [5.7 11.3]	253	7.9 [5.5 11.2]	355	8.2 [5.8 11.5] 0.684
Monocytes	x10 ⁹ /L	604	0.4 [0.3 0.7]	252	0.5 [0.3 0.7]	352	0.4 [0.3 0.7] 0.048
Lymphocytes	x10 ⁹ /L	605	0.8 [0.5 1.2]	253	0.8 [0.6 1.3]	352	0.8 [0.5 1.1] 0.035
Basophils	x10 ⁹ /L	488	0.0 [0.0 0.1]	197	0.0 [0.0 0.1]	291	0.0 [0.0 0.1] 0.215
Eosinophils	x10 ⁹ /L	483	0.0 [0.0 0.1]	201	0.1 [0.0 0.1]	282	0.0 [0.0 0.1] 0.002
Coag							
Platelet Count	μmol/L	609	247.0 [186.8 321.0]	253	249.0 [191.8 328.3]	356	246.0 [182.5 318.5] 0.320
APTT	U/L	389	32.0 [28.3 37.1]	158	32.0 [28.3 37.8]	231	32.0 [28.2 36.5] 0.763
PT	U/L	387	13.8 [12.4 15.2]	158	13.6 [12.1 15.1]	229	13.9 [12.7 15.2] 0.438
INR	U/L	211	1.1 [1.1 1.2]	97	1.1 [1.1 1.2]	114	1.1 [1.0 1.2] 0.367
Fibrinogen	U/L	401	6.8 [5.6 8.1]	175	6.6 [5.7 7.7]	226	6.9 [5.6 8.3] 0.214
D-dimer	U/L	388	2605.5 [991.0 7647.5]	176	2924.5 [980.5 8159.5]	212	2403.0 [1050.0 7495.0] 0.822
Electrolytes							
Blood Urea Nitrogen (BUN)	mmol/L	488	7.4 [4.9 11.7]	196	6.8 [4.4 10.8]	292	7.8 [5.3 12.0] 0.017
Creatinine	μmol/L	611	88.0 [66.0 139.8]	254	84.0 [64.0 129.0]	357	89.0 [67.0 145.8] 0.057
Sodium	mmol/L	611	139.0 [136.0 142.0]	255	139.0 [137.0 142.0]	356	138.0 [135.0 141.0] 0.002
Potassium	mmol/L	610	4.4 [4.0 4.8]	254	4.4 [4.0 4.8]	356	4.4 [4.1 4.8] 0.610
Liver							
Bilirubin	μmol/L	579	10.0 [7.0 15.0]	248	10.0 [7.0 14.0]	331	10.0 [7.0 15.0] 0.189
Alkaline Phosphatase	U/L	591	77.0 [58.3 113.0]	251	79.0 [58.3 121.4]	340	75.5 [58.5 107.0] 0.297
AST	U/L	97	59.0 [38.5 85.0]	43	56.0 [34.8 69.5]	54	62.0 [41.0 90.0] 0.147
ALT	U/L	584	37.0 [24.0 59.0]	248	36.5 [23.0 60.5]	336	37.0 [24.0 59.0] 0.795
Inflammation							
LDH (Lactate dehydrogenase)	U/L	192	649.0 [459.5 923.3]	81	679.0 [467.8 1046.5]	111	609.0 [455.8 875.0] 0.163
Ferritin	ng/mL	288	1218.5 [693.5 2333.0]	128	1019.5 [659.5 2088.5]	160	1392.0 [777.0 2497.5] 0.028
CRP		586	216.4 [135.0 311.7]	252	207.5 [118.5 309.4]	334	220.5 [146.0 313.0] 0.149
Procalcitonin	ug/L	118	0.7 [0.3 2.1]	58	0.6 [0.3 2.2]	60	0.8 [0.3 2.1] 0.398
Cardiac							
Creatinine Kinase	U/L	242	219.0 [85.0 638.0]	107	197.0 [79.0 571.0]	135	226.0 [95.8 664.8] 0.261
High sensitivity Troponin		249	21.8 [10.9 60.3]	115	18.0 [9.0 50.0]	134	25.4 [12.0 61.0] 0.110
NT Pro BNP	pg/ml	58	537.5 [165.0 1478.0]	28	454.0 [196.5 1498.5]	30	611.0 [161.0 1478.0] 0.834
Fluid							
Cumulative Fluid balance	L	574	332.1 [-224.0 1031.8]	250	274.9 [-267.0 985.0]	324	359.0 [-210.5 1105.5] 0.365
Adjunctive interventions							
Was patient transferred in?		623	159 (25.5%)	263	79 (30%)	360	80 (22.2%) 0.027
Tracheostomy		506	145 (28.7%)	216	59 (27.3%)	290	86 (29.7%) 0.671
PEEP>10		612	450 (73.5%)	258	155 (60.1%)	354	295 (83.3%) 0.000
Neuro-muscular blockade		607	427 (70.3%)	252	148 (58.7%)	355	279 (78.6%) 0.000
Prone positioning		541	268 (49.5%)	230	87 (37.8%)	311	181 (58.2%) 0.000
Inhaled nitric oxide		511	73 (14.3%)	220	21 (9.55%)	291	52 (17.9%) 0.013
Inhaled prostacyclin		511	54 (10.6%)	220	17 (7.73%)	291	37 (12.7%) 0.095
Bronchoscopy		511	49 (9.59%)	220	19 (8.64%)	291	30 (10.3%) 0.612
Renal replacement therapy		545	206 (37.8%)	234	72 (30.8%)	311	134 (43.1%) 0.010
Diuretics		588	442 (75.2%)	243	171 (70.4%)	345	271 (78.6%) 0.005
Corticosteroids		572	302 (52.8%)	243	115 (47.3%)	329	187 (56.8%) 0.043
Therapeutic heparin		428	55 (12.9%)	172	18 (10.5%)	256	37 (14.5%) 0.136
Antibiotics		303	211 (69.6%)	123	70 (56.9%)	180	141 (78.3%) 0.001
Prone							
No of proning episodes		268	1.0 [1.0 2.0]	87	1.0 [1.0 2.0]	181	1.0 [1.0 2.0] 0.836
mech vent prior first prone	days	268	3.0 [1.5 6.0]	87	2.0 [1.0 5.0]	181	4.0 [2.0 7.0] 0.006
durationn of first prone	days	268	2.0 [1.0 4.0]	87	2.0 [1.0 4.0]	181	2.0 [1.0 4.0] 0.796
responders to proning		266	118 (44.4%)	86	52 (60.5%)	180	66 (36.7%) 0.651
Tracheostomy							
mech vent prior to tracheostomy	days	145	13.0 [9.0 18.0]	59	13.0 [7.0 16.0]	86	15.0 [10.0 19.0] 0.015
durationn of tracheostomy	days	145	14.0 [6.0 21.3]	59	11.0 [4.3 22.0]	86	15.0 [8.0 21.0] 0.078

Table S7 - Time series mixed model ANOVA according to resolution of hypoxaemia over first week of mechanical ventilation.

label	N	p-values		
		Resolvers vs Non-Resolvers	parameter over time	interaction
PaO ₂ / FiO ₂	468	0.000	0.000	0.000
Dynamic Compliance	337	0.358	0.028	0.199
Respiratory rate	454	0.520	0.000	0.625
FiO ₂ (%)	499	0.000	0.000	0.000
Tidal Volume per Kg	346	0.856	0.410	0.621
Tidal Volume	429	0.255	0.568	0.622
Minute ventilation	400	0.319	0.000	0.535
Peak pressure	422	0.001	0.000	0.000
PEEP	386	0.000	0.000	0.000
Dynamic delta pressure (peakP-peep)	124	0.559	0.813	0.197
Mean airway pressure	255	0.004	0.000	0.000
I:E ratio	93	0.280	0.487	0.458
Pressure support	165	0.199	0.013	0.035
Oxygen saturation	413	0.000	0.185	0.001
pH	483	0.000	0.000	0.002
PaO ₂	480	0.011	0.023	0.000
PaCO ₂	309	0.111	0.015	0.000
Base excess	474	0.038	0.000	0.062
HCO ₃ ⁻	475	0.104	0.000	0.006
Lactate	447	0.003	0.342	0.029
Oxygenation Index	236	0.000	0.000	0.000
Ventilatory Ratio	167	0.390	0.495	0.227
Mean arterial pressure (lowest)	382	0.002	0.000	0.001
Liver-Bilirubin	167	0.262	0.040	0.158
Daily fluid balance	470	0.001	0.000	0.122
Cumulative fluid balance	470	0.009	0.077	0.002
SOFA Score	191	0.117	0.000	0.000
Non-Respiratory SOFA	223	0.292	0.000	0.001
Glucose	461	0.110	0.005	0.034
BUN	378	0.002	0.013	0.003
Creatinine	516	0.025	0.053	0.000
Sodium	519	0.597	0.007	0.287
Potassium	514	0.009	0.191	0.157
Bilirubin	400	0.271	0.000	0.002
Alkaline Phosphatase	438	0.165	0.000	0.671
AST	55	0.914	0.743	0.279
ALT	418	0.226	0.000	0.098
Creatinine Kinase	127	0.921	0.174	0.580
LDH	66	0.182	0.046	0.397
Haemoglobin	511	0.902	0.281	0.082
WBC	509	0.541	0.050	0.242
RBC	411	0.818	0.850	0.698
Platelet Count	507	0.040	0.000	0.107
Haematocrit	249	0.914	0.000	0.021
Neutrophils	507	0.974	0.457	0.287
Monocytes	505	0.004	0.000	0.392
Lymphocytes	505	0.117	0.000	0.015
Basophils	357	0.161	0.226	0.662
Eosinophils	382	0.001	0.000	0.584
APTT	255	0.236	0.660	0.326
PT	260	0.912	0.456	0.431
INR	163	0.815	0.175	0.440
Fibrinogen	137	0.063	0.062	0.690
Ferritin	75	0.201	0.472	0.404
D-dimer	147	0.967	0.388	0.406
CRP	456	0.001	0.000	0.000
High sensitivity Troponin	62	0.704	0.596	0.790

Table S8 - Uni- and multi-variate model analysis of factors associated with progression of hypoxaemia over the first week of invasive mechanical ventilation

FieldLabel	median [IQR]	Univariate			Multivariate				
		Odds ratio	95% CI	P Value	Odds ratio	95% CI	P Value		
Age	(per decade)	1.395	1.210	1.608	0.000	1.257	1.077	1.466	0.004
Male		1.351	0.909	2.007	0.136				
BMI	28.08 [24.90 32.70]	0.920	0.784	1.080	0.310				
Weight	84.00 [75.00 95.00]	0.923	0.792	1.075	0.304				
Height	173.00 [165.00 178.00]	0.929	0.789	1.094	0.377				
symptoms days	8.00 [6.00 12.00]	0.860	0.728	1.017	0.078	0.961	0.801	1.153	0.667
Hypertension		1.186	0.838	1.677	0.336				
COPD		1.766	0.828	3.768	0.141				
Diabetes mellitus		1.654	1.116	2.451	0.012	1.492	0.973	2.287	0.067
CKD		1.566	0.587	4.183	0.371				
Solid tumour		0.850	0.361	2.001	0.709				
Oxygen saturation	95.00 [93.00 98.00]	0.838	0.714	0.984	0.031	0.953	0.797	1.138	0.593
pH	7.36 [7.30 7.42]	0.901	0.775	1.049	0.180				
PaCO ₂	6.20 [5.30 7.58]	1.020	0.871	1.195	0.807				
HCO ⁻³	24.50 [22.50 26.70]	0.769	0.659	0.898	0.001	0.850	0.717	1.008	0.062
Lactate	1.20 [1.00 1.60]	1.178	1.009	1.376	0.039	0.993	0.830	1.187	0.938
Peak pressure	26.00 [23.00 30.00]	1.193	1.022	1.394	0.025	1.182	0.986	1.418	0.071
PEEP	10.00 [8.00 12.00]	1.286	1.084	1.526	0.004	1.104	0.898	1.358	0.346
Minute ventilation	8.49 [6.85 10.37]	1.014	0.872	1.179	0.855				
Dynamic Comp	31.44 [24.26 40.15]	0.917	0.785	1.071	0.274				
Oxygenation Index	8.11 [5.10 12.59]	1.037	0.880	1.221	0.667				
Cum fluid balance	332.10 [-224.00 1031.80]	1.106	0.949	1.289	0.199				
Neutrophils	8.05 [5.71 11.30]	1.093	0.940	1.273	0.248				
Monocytes	0.41 [0.30 0.70]	0.840	0.723	0.976	0.023	0.931	0.785	1.106	0.417
Eosinophils	0.00 [0.00 0.10]	0.474	0.333	0.676	0.000	0.606	0.403	0.911	0.016
APTT	32.00 [28.28 37.10]	0.979	0.830	1.155	0.803				
PT	13.80 [12.40 15.20]	1.031	0.871	1.220	0.721				
Fibrinogen	6.80 [5.60 8.10]	1.144	0.971	1.347	0.107				
D-dimer	2605.50 [991.00 7647.50]	0.895	0.759	1.054	0.184				
BUN	7.40 [4.90 11.70]	1.250	1.070	1.460	0.005	1.191	0.992	1.430	0.060
Sodium	139.00 [136.00 142.00]	0.784	0.671	0.916	0.002	0.810	0.680	0.966	0.019
Potassium	4.40 [4.00 4.80]	1.075	0.922	1.252	0.357				
ALP	77.00 [58.25 113.00]	0.953	0.820	1.107	0.526				
ALT	37.00 [24.00 59.00]	1.039	0.894	1.208	0.616				
CRP	216.40 [135.00 311.70]	1.143	0.981	1.333	0.087	1.024	0.860	1.218	0.791
SOFA Respiratory		0.967	0.805	1.162	0.722				
SOFA Nervous		1.030	0.945	1.124	0.500				
SOFA Cardio		1.241	1.069	1.440	0.004	1.200	1.014	1.421	0.034
SOFA Liver		0.966	0.705	1.325	0.832				
SOFA Coagulation		1.251	0.890	1.758	0.197				
SOFA Kidneys		1.072	0.913	1.258	0.396				
SOFA score		1.039	0.970	1.113	0.277				

Table S9 - Clinical and physiological characteristics, outcomes and interventions according to prone responsiveness.

Clinical Characteristics			Prone responsiveness					
		ALL	Responders		Non-Responders			
label	units	Total N	median [IQR]	N (%)	N	median [IQR]	N (%)	P Value
Male		266	200 [75.2%]	118	92 (78%)	148	108 (73%)	0.349
White		215	111 [51.6%]	89	42 (47.2%)	126	69 (54.8%)	0.070
Age	years	266	60.0 [54.0 65.0]	118	58.0 [50.0 64.0]	148	60.0 [56.0 66.0]	0.002
BMI	kg/m ²	237	28.7 [25.2 33.1]	106	29.4 [26.2 33.0]	131	28.0 [24.7 33.3]	0.242
Time since onset of symptoms	days	178	7.0 [6.0 11.0]	74	8.0 [6.0 13.0]	104	7.0 [6.0 11.0]	0.283
ICU length of stay	days	266	18.0 [11.0 29.0]	118	19.0 [12.0 31.0]	148	16.0 [10.0 26.5]	0.061
Length of mechanical ventilation	days	266	16.0 [11.0 26.0]	118	18.0 [11.0 29.0]	148	15.0 [10.0 24.0]	0.075
ICU Mortality	%	266	137 (51.5%)	118	35 (29.7%)	148	102 (68.9%)	0.000
Vent								
FIO ₂ (%)		265	65.0 [50.0 80.0]	118	60.0 [50.0 80.0]	147	70.0 [60.0 80.0]	0.020
PaO ₂ to FIO ₂ ratio		265	16.4 [12.2 21.9]	118	17.9 [13.7 23.4]	147	15.1 [11.5 19.6]	0.000
Tidal Volume (mls/IBW)	ml/Kg(IBW)	219	6.8 [6.1 7.8]	99	6.8 [6.2 7.9]	120	6.8 [6.0 7.7]	0.639
Respiratory rate	bpm	264	20.0 [16.0 24.0]	117	20.0 [18.0 24.0]	147	18.0 [16.0 22.0]	0.015
Minute ventilation	L/minute	252	8.7 [6.9 10.5]	114	9.1 [7.7 10.6]	138	8.4 [6.6 10.1]	0.020
Peak pressure	ml/Kg(RBW)	252	27.0 [24.0 30.0]	116	27.0 [24.0 29.0]	136	28.0 [25.0 31.0]	0.042
Plateau pressure	ml/Kg(BW)	46	28.0 [24.0 29.0]	19	25.0 [22.0 29.8]	27	28.0 [25.3 28.0]	0.605
PEEP	cmH ₂ O	255	10.0 [10.0 12.0]	115	10.0 [10.0 12.0]	140	11.4 [10.0 14.0]	0.083
Mean airway pressure	cmH ₂ O	142	17.0 [14.0 19.0]	73	17.0 [15.0 18.0]	69	16.0 [14.0 21.3]	0.809
Pressure support	cmH ₂ O	146	10.0 [8.0 14.0]	59	10.0 [8.0 15.0]	87	10.0 [8.0 14.0]	0.393
Dynamic Compliance	mls/cmH2O	233	30.0 [24.0 38.1]	108	31.0 [23.5 39.4]	125	29.5 [24.5 36.7]	0.653
Oxygenation Index		142	9.5 [6.4 13.6]	73	8.7 [5.9 11.1]	69	11.1 [7.2 16.3]	0.002
Ventilatory Ratio		154	1.9 [1.6 2.3]	72	1.8 [1.6 2.2]	82	2.0 [1.6 2.4]	0.343
ABG								
Oxygen saturation		238	95.0 [92.0 97.0]	112	95.0 [92.0 97.0]	126	94.0 [92.0 96.0]	0.208
pH		266	7.4 [7.3 7.4]	118	7.3 [7.3 7.4]	148	7.4 [7.3 7.4]	0.951
PaO ₂	kPa	266	10.5 [9.0 12.5]	118	10.5 [9.2 12.7]	148	10.6 [8.8 12.3]	0.534
PaCO ₂	kPa	202	6.4 [5.5 7.5]	92	6.2 [5.3 7.6]	110	6.5 [5.7 7.5]	0.395
Base excess		266	0.2 [-2.5 2.7]	118	0.2 [-2.4 2.4]	148	0.2 [-2.6 3.2]	0.734
HCO ₃	mmol/L	265	24.5 [22.4 27.0]	117	24.6 [22.4 26.7]	148	24.3 [22.4 27.1]	0.588
Lactate	mmol/L	252	1.2 [1.0 1.6]	109	1.1 [0.9 1.5]	143	1.3 [1.1 1.7]	0.000
SOFA								
SOFA score		171	9.0 [7.0 11.0]	74	8.0 [7.0 10.0]	97	9.0 [7.0 11.0]	0.243
SOFA Respiratory		265	3.0 [3.0 4.0]	118	3.0 [3.0 3.0]	147	3.0 [3.0 4.0]	0.000
SOFA Nervous		201	4.0 [0.0 4.0]	87	4.0 [0.0 4.0]	114	3.0 [0.0 4.0]	0.173
SOFA Cardiovascular		244	3.0 [1.0 4.0]	109	3.0 [1.0 3.0]	135	3.0 [3.0 4.0]	0.000
SOFA Liver		249	0.0 [0.0 0.0]	109	0.0 [0.0 0.0]	140	0.0 [0.0 0.0]	0.860
SOFA Coagulation		263	0.0 [0.0 0.0]	115	0.0 [0.0 0.0]	148	0.0 [0.0 0.0]	0.848
SOFA Kidneys		265	0.0 [0.0 1.0]	117	0.0 [0.0 1.0]	148	0.0 [0.0 1.0]	0.240
FBC								
Haemoglobin	g/dL	263	116.0 [92.5 128.0]	115	116.0 [96.5 127.9]	148	117.0 [90.0 129.5]	0.786
Haematocrit		174	0.4 [0.3 0.4]	85	0.4 [0.3 0.4]	89	0.4 [0.3 0.4]	0.747
White blood cell count	x10 ⁹ /L	263	9.7 [7.3 12.8]	115	9.6 [7.1 12.6]	148	9.8 [7.5 12.9]	0.682
Neutrophils	x10 ⁹ /L	263	8.3 [6.1 11.3]	115	8.0 [5.6 11.1]	148	8.3 [6.5 11.6]	0.362
Monocytes	x10 ⁹ /L	260	0.4 [0.3 0.6]	114	0.4 [0.3 0.6]	146	0.4 [0.3 0.6]	0.759
Lymphocytes	x10 ⁹ /L	261	0.7 [0.5 1.1]	114	0.8 [0.5 1.2]	147	0.7 [0.5 1.1]	0.552
Basophils	x10 ⁹ /L	219	0.0 [0.0 0.1]	99	0.0 [0.0 0.1]	120	0.0 [0.0 0.0]	0.445
Eosinophils	x10 ⁹ /L	216	0.0 [0.0 0.1]	100	0.0 [0.0 0.1]	116	0.0 [0.0 0.1]	0.390
Coag								
Platelet Count	μmL/L	263	247.0 [191.0 331.0]	115	249.0 [197.0 329.8]	148	247.0 [190.0 333.0]	0.754
APTT	U/L	189	31.7 [28.0 35.3]	85	31.8 [28.0 35.6]	104	31.3 [27.8 34.7]	0.419
PT	U/L	188	13.5 [12.1 14.9]	85	13.2 [12.1 14.7]	103	13.6 [12.0 15.3]	0.239
INR	U/L	127	1.1 [1.1 1.2]	66	1.1 [1.1 1.2]	61	1.1 [1.1 1.2]	0.521
Fibrinogen	U/L	184	6.9 [5.7 8.2]	92	6.9 [5.5 8.0]	92	7.2 [6.0 8.3]	0.106
D-dimer	U/L	170	2496.5 [947.0 6289.0]	73	1694.0 [880.0 3895.0]	97	3142.0 [1381.3 8441.8]	0.010
Electrolytes								
Blood Urea Nitrogen (BUN)	mmol/L	185	6.8 [5.0 10.7]	66	6.6 [5.0 10.1]	119	7.4 [5.0 12.1]	0.464
Creatinine	μmol/L	263	84.0 [63.0 124.8]	116	85.0 [65.5 133.5]	147	82.0 [63.0 117.3]	0.304
Sodium	mmol/L	264	138.0 [136.0 141.0]	117	138.0 [135.0 140.3]	147	139.0 [136.0 142.8]	0.196
Potassium	mmol/L	264	4.4 [4.1 4.7]	117	4.5 [4.2 4.8]	147	4.4 [4.0 4.7]	0.215
Liver								
Bilirubin	μmol/L	249	10.0 [7.0 15.0]	109	10.0 [7.0 15.0]	140	10.0 [8.0 15.0]	0.283
Alkaline Phosphatase	U/L	254	76.0 [56.0 109.0]	112	76.0 [53.0 111.0]	142	75.0 [60.0 107.0]	0.627
AST	U/L	51	61.0 [41.0 81.3]	22	59.0 [42.0 91.0]	29	62.0 [39.8 79.8]	0.909
ALT	U/L	250	37.0 [26.0 57.0]	110	37.0 [26.0 58.0]	140	37.5 [25.5 56.0]	0.940
Inflammation								
LDH (Lactate dehydrogenase)	U/L	109	71.0 [51.0 100.0]	55	78.0 [53.2.0 114.8]	54	67.7.0 [51.2.0 97.1.0]	0.400
Ferritin	ng/mL	148	1297.0 [710.5 2526.0]	68	1038.0 [629.5 2215.0]	80	1444.5 [762.5 2785.5]	0.111
CRP		250	236.5 [159.0 323.0]	116	231.5 [155.0 323.5]	134	241.2 [163.0 322.3]	0.550
Procalcitonin	ug/L	43	0.7 [0.4 2.4]	18	0.5 [0.3 2.3]	25	1.1 [0.5 2.7]	0.192
Cardiac								
Creatinine Kinase	U/L	122	248.5 [122.0 638.0]	61	373.0 [187.1 847.3]	61	155.0 [92.8 515.8]	0.004
High sensitivity Troponin		131	21.8 [11.7 54.2]	65	15.0 [8.5 50.8]	66	25.0 [14.2 61.0]	0.027
NT Pro BNP	pg/ml	26	621.0 [173.0 1983.0]	10	313.5 [165.0 680.0]	16	810.5 [502.0 2587.0]	0.058
Fluid								
Cumulative Fluid balance	L	246	383.2 [-198.1 1157.0]	107	167.0 [-276.1 757.7]	139	613.0 [-121.5 1340.8]	0.010
Adjunctive interventions								
Was patient transferred in?		266	87 (32.7%)	118	48 (40.7%)	148	39 (26.4%)	0.013
Tracheostomy		239	77 (32.2%)	112	41 (36.6%)	127	36 (28.3%)	0.063
PEEP>10		264	235 (89%)	118	101 (85.6%)	146	134 (91.8%)	0.212
Neuro-muscular blockade		265	242 (91.3%)	117	106 (90.6%)	148	136 (91.9%)	0.560
Prone positioning		266	266 (100%)	118	118 (100%)	148	148 (100%)	
Inhaled nitric oxide		239	66 (27.6%)	112	20 (17.9%)	127	46 (36.2%)	0.008
Inhaled prostacyclin		239	35 (14.6%)	112	9 (8.04%)	127	26 (20.5%)	0.017
Bronchoscopy		239	33 (13.8%)	112	18 (16.1%)	127	15 (11.8%)	0.208
Renal replacement therapy		246	109 (44.3%)	114	47 (41.2%)	132	62 (47%)	0.734
Diuretics		264	209 (79.2%)	117	90 (76.9%)	147	119 (81%)	0.414
Corticosteroids		260	153 (58.8%)	117	65 (55.6%)	143	88 (61.5%)	0.473
Therapeutic heparin		183	33 (18%)	74	14 (18.9%)	109	19 (17.4%)	0.811
Antibiotics		175	115 (65.7%)	86	45 (52.3%)	89	70 (78.7%)	0.134
Prone								
No of proning episodes		266	1.0 [1.0 2.0]	118	1.0 [1.0 2.0]	148	1.0 [1.0 2.0]	0.060
mech vent prior first prone	days	266	3.0 [1.0 6.0]	118	3.0 [2.0 6.0]	148	3.0 [1.0 7.0]	0.427
durationn of first prone	days	266	2.0 [1.0 4.0]	118	2.0 [1.0 4.0]	148	2.0 [1.0 4.0]	0.493
responders to proning		266	118 (44.4%)	118	118 (100%)	148	0 (0%)	0.000
Tracheostomy								
mech vent prior to tracheostomy	days	77	16.0 [11.0 20.0]	41	16.0 [12.0 19.3]	36	14.5 [8.5 20.0]	0.352
durationn of tracheostomy	days	77	14.0 [6.0 21.3]	41	15.0 [7.8 22.0]	36	11.5 [4.0 20.0]	0.129

Table S10 - Time series mixed model ANOVA according to prone responsiveness.

label	N	p-values		
		Prone Responders vs non-Responders	parameter over time	interaction
PaO ₂ / FiO ₂	197	0.000	0.000	0.000
Dynamic Compliance	141	0.109	0.343	0.533
Respiratory rate	183	0.422	0.050	0.031
FiO ₂ (%)	201	0.000	0.000	0.000
Tidal Volume per Kg	158	0.278	0.655	0.485
Tidal Volume	181	0.194	0.529	0.834
Minute ventilation	166	0.153	0.014	0.076
Peak pressure	179	0.000	0.000	0.001
PEEP	160	0.042	0.016	0.149
Dynamic delta pressure (peakP-peep)	68	0.042	0.341	0.741
Mean airway pressure	104	0.049	0.000	0.001
I:E ratio	33	0.566	0.568	0.468
Pressure support	62	0.175	0.108	0.150
Oxygen saturation	188	0.000	0.194	0.280
pH	203	0.003	0.000	0.002
PaO ₂	203	0.000	0.000	0.013
PaCO ₂	152	0.001	0.006	0.000
Base excess	197	0.403	0.146	0.873
HCO ₃ ⁻	202	0.583	0.607	0.646
Lactate	182	0.000	0.388	0.336
Oxygenation Index	100	0.000	0.000	0.000
Ventilatory Ratio	95	0.004	0.437	0.044
Mean arterial pressure (lowest)	167	0.112	0.154	0.336
Liver-Bilirubin	65	0.547	0.638	0.525
Daily fluid balance	172	0.050	0.324	0.201
Cumulative fluid balance	172	0.351	0.469	0.126
SOFA Score	91	0.019	0.180	0.250
Non-Respiratory SOFA	96	0.085	0.390	0.556
Glucose	181	0.522	0.322	0.492
BUN	138	0.870	0.192	0.260
Creatinine	215	0.738	0.575	0.217
Sodium	220	0.034	0.519	0.339
Potassium	216	0.603	0.177	0.240
Bilirubin	170	0.466	0.301	0.328
Alkaline Phosphatase	178	0.706	0.232	0.876
ALT	176	0.378	0.003	0.038
Creatinine Kinase	73	0.231	0.241	0.364
LDH	43	0.736	0.497	0.106
Haemoglobin	219	0.358	0.009	0.384
WBC	219	0.267	0.022	0.225
RBC	197	0.213	0.579	0.362
Platelet Count	218	0.076	0.000	0.054
Haematocrit	146	0.643	0.001	0.343
Neutrophils	219	0.126	0.466	0.276
Monocytes	219	0.392	0.002	0.808
Lymphocytes	219	0.445	0.227	0.373
Basophils	175	0.471	0.420	0.418
Eosinophils	177	0.643	0.305	0.202
APTT	125	0.670	0.546	0.654
PT	129	0.484	0.953	0.529
INR	99	0.723	0.207	0.087
Fibrinogen	82	0.665	0.854	0.890
Ferritin	54	0.249	0.467	0.269
D-dimer	60	0.329	0.566	0.358
CRP	195	0.048	0.000	0.022
High sensitivity Troponin	54	0.645	0.575	0.622

Table S11 - Uni- and multi-variate model analysis of pre-pronation factors associated prone responsiveness.

FieldLabel	median [IQR]	Univariate			Multivariate				
		Odds ratio	95% CI	P Value	Odds ratio	95% CI	P Value		
Age (per decade)	1.503	1.165	1.939	0.002	1.354	0.992	1.847	0.056	
Male	0.740	0.401	1.364	0.335					
BMI	28.73 [25.24 33.07]	0.853	0.671	1.086	0.197				
Weight	85.00 [75.00 95.00]	0.780	0.613	0.993	0.043	0.741	0.543	1.010	0.058
Height	172.00 [165.00 178.00]	1.009	0.789	1.290	0.943				
symptoms days	7.00 [6.00 11.00]	0.903	0.693	1.176	0.449				
Hypertension		1.131	0.657	1.949	0.656				
Diabetes mellitus		1.197	0.644	2.223	0.569				
Prone initiation day	1.00 [-1.00 4.00]	1.168	0.855	1.594	0.329				
Oxygen saturation	93.00 [91.00 96.00]	0.748	0.582	0.961	0.023	1.045	0.740	1.477	0.802
pH	7.37 [7.31 7.42]	0.867	0.685	1.099	0.238				
PaCO_2	6.79 [5.96 7.83]	1.515	1.161	1.976	0.002	1.240	0.882	1.742	0.215
HCO^-3	26.80 [24.00 30.77]	1.014	0.802	1.281	0.908				
Lactate	1.30 [1.10 1.80]	1.736	1.351	2.232	0.000	1.408	1.030	1.925	0.032
Peak pressure	28.56 [25.00 31.00]	1.601	1.251	2.049	0.000	1.367	1.000	1.869	0.050
PEEP	10.20 [10.00 13.00]	1.369	1.064	1.762	0.015	1.352	0.960	1.905	0.085
Minute ventilation	9.88 [8.16 12.00]	0.989	0.775	1.261	0.927				
Dynamic Comp	29.70 [23.58 37.39]	0.907	0.706	1.165	0.445				
Cum fluid balance	1778.00 [204.24 4277.40]	1.469	1.145	1.885	0.003	1.083	0.792	1.482	0.616
Neutrophils	8.75 [6.90 11.70]	1.164	0.921	1.471	0.205				
Monocytes	0.40 [0.30 0.70]	0.923	0.722	1.181	0.525				
Eosinophils	0.10 [0.00 0.20]	0.918	0.661	1.275	0.610				
APTT	33.00 [29.00 38.92]	0.891	0.692	1.149	0.375				
PT	13.90 [12.10 15.30]	1.064	0.831	1.364	0.623				
BUN	10.05 [6.85 15.60]	1.010	0.794	1.286	0.934				
Sodium	141.00 [139.00 146.00]	1.234	0.978	1.558	0.077	1.261	0.924	1.722	0.143
Potassium	4.55 [4.30 4.95]	1.083	0.852	1.377	0.516				
ALP	85.00 [63.00 137.00]	0.985	0.774	1.255	0.905				
ALT	40.00 [27.00 59.00]	0.785	0.617	1.000	0.050	0.880	0.645	1.202	0.422
CRP	281.00 [185.50 340.25]	1.109	0.876	1.403	0.392				
SOFA Respiratory		4.813	2.667	8.688	0.000	3.587	1.827	7.044	0.000
SOFA Nervous		1.010	0.878	1.161	0.891				
SOFA Cardio		1.518	1.223	1.884	0.000	1.374	1.049	1.801	0.021
SOFA Liver		0.998	0.661	1.505	0.991				
SOFA Coagulation		1.582	0.840	2.979	0.155				
SOFA Kidneys		0.945	0.746	1.197	0.639				

Table S12 - Uni- and multi-variate model analysis of post- pronation factors associated prone responsiveness.

FieldLabel	median [IQR]	Univariate			Multivariate				
		Odds ratio	95% CI	P Value	Odds ratio	95% CI	P Value		
Age (per decade)		1.420	1.072	1.881	0.015	1.418	1.017	1.976	0.039
Male		1.009	0.505	2.013	0.980				
BMI	28.73 [25.24 33.07]	0.896	0.685	1.171	0.420				
Weight	85.00 [75.00 95.00]	0.882	0.674	1.154	0.361				
Height	172.00 [165.00 178.00]	1.025	0.786	1.336	0.855				
symptoms days	7.00 [6.00 11.00]	0.965	0.723	1.290	0.812				
Hypertension		1.586	0.874	2.880	0.129				
Diabetes mellitus		1.697	0.888	3.245	0.110				
Prone initiation day	2.00 [0.00 5.00]	1.504	1.016	2.226	0.041	1.236	0.775	1.971	0.373
Oxygen saturation	93.00 [91.00 95.00]	0.675	0.514	0.888	0.005	0.754	0.546	1.043	0.088
pH	7.36 [7.31 7.42]	0.870	0.671	1.129	0.295				
HCO ⁻³	28.00 [24.60 31.00]	1.090	0.841	1.412	0.514				
Lactate	1.40 [1.10 1.80]	1.681	1.263	2.238	0.000	1.369	0.983	1.906	0.063
Peak pressure	28.00 [25.00 31.00]	1.362	1.034	1.792	0.028	1.214	0.879	1.675	0.239
PEEP	11.00 [10.00 13.13]	1.370	1.039	1.806	0.026	1.609	1.143	2.263	0.006
Minute ventilation	10.06 [8.02 11.57]	1.088	0.836	1.415	0.531				
Dynamic Comp	30.44 [21.83 41.19]	0.988	0.754	1.294	0.930				
SOFA Respiratory		2.220	1.295	3.808	0.004	2.142	1.137	4.036	0.018
SOFA Nervous		0.891	0.765	1.039	0.141				
SOFA Cardio		1.577	1.214	2.049	0.001	1.428	1.057	1.928	0.020
SOFA Liver		1.064	0.648	1.749	0.805				
SOFA Coagulation		1.546	0.842	2.838	0.160				
SOFA Kidneys		0.973	0.758	1.247	0.827				

Table S13- Clinical and physiological characteristics, outcomes and interventions according to ICU outcome.

Clinical Characteristics			Outcome					
		ALL	Survivors			Non-Survivors		P Value
label	units	Total N	median [IQR] / N (%)	N	median [IQR] / N (%)	N	median [IQR] / N (%)	
Male		623	474 (76.1%)	366	264 (72.1%)	257	210 (81.7%)	0.006
White		532	240 (45.1%)	310	142 (45.8%)	222	98 (44.1%)	0.867
Age	years	623	59.0 [51.0 66.0]	366	56.0 [47.0 63.0]	257	63.0 [57.0 70.0]	0.000
BMI	kg/m ²	516	28.1 [24.9 32.7]	315	28.7 [25.1 33.5]	201	27.8 [24.7 31.2]	0.165
Time since onset of symptoms	days	399	8.0 [6.0 12.0]	241	9.0 [6.0 12.0]	158	7.0 [5.0 12.0]	0.110
ICU length of stay	days	623	14.0 [8.0 23.0]	366	17.0 [10.0 30.0]	257	11.0 [7.0 18.0]	0.000
Length of mechanical ventilation	days	623	13.0 [7.3 22.0]	366	15.0 [8.0 28.0]	257	11.0 [7.0 16.3]	0.000
ICU Mortality	%	623	257 (41.3%)	366	0 (0%)	257	257 (100%)	0.000
Vent								
FiO ₂ (%)		618	60.0 [45.0 80.0]	361	55.0 [40.0 70.0]	257	65.0 [55.0 80.0]	0.000
PaO ₂ to FiO ₂ ratio		616	18.4 [13.0 25.1]	360	19.8 [13.9 27.5]	256	16.9 [12.3 23.0]	0.000
Tidal Volume (mls/IBW)	ml/Kg(IBW)	471	6.8 [6.0 7.8]	288	6.9 [6.1 7.8]	183	6.8 [6.0 7.8]	0.400
Respiratory rate	bpm	617	18.0 [16.0 22.0]	361	18.0 [16.0 22.0]	256	19.1 [16.0 22.0]	0.563
Minute ventilation	l/minute	596	8.5 [6.9 10.4]	349	8.5 [6.9 10.4]	247	8.6 [6.8 10.3]	0.726
Peak pressure	ml/kg(RBW)	589	26.0 [23.0 30.0]	345	26.0 [22.0 29.0]	244	27.0 [24.0 30.0]	0.000
Plateau pressure	ml/kg(IBW)	78	25.5 [22.0 28.0]	37	24.0 [20.8 28.0]	41	26.0 [24.0 29.0]	0.012
PEEP	cmH ₂ O	593	10.0 [8.0 12.0]	348	10.0 [8.0 12.0]	245	10.0 [10.0 12.0]	0.000
Mean airway pressure	cmH ₂ O	384	16.0 [13.3 19.0]	241	15.2 [13.0 18.0]	143	17.0 [14.0 20.0]	0.001
Pressure support	cmH ₂ O	362	10.0 [6.0 14.0]	216	10.0 [6.0 14.0]	146	10.0 [6.0 12.0]	0.644
Dynamic Compliance	mls/cmH2O	555	31.4 [24.3 40.1]	328	32.5 [25.3 41.0]	227	30.0 [23.1 39.2]	0.048
Oxygenation Index		384	8.1 [5.1 12.6]	241	7.2 [4.7 10.4]	143	9.9 [6.5 14.4]	0.000
Ventilatory Ratio		261	1.8 [1.4 2.2]	145	1.8 [1.4 2.2]	116	1.9 [1.4 2.3]	0.609
ABG								
Oxygen saturation		508	95.0 [93.0 98.0]	309	96.0 [93.0 98.0]	199	95.0 [92.0 97.0]	0.007
pH		620	7.4 [7.3 7.4]	364	7.4 [7.3 7.4]	256	7.3 [7.3 7.4]	0.000
PaO ₂	kPa	620	10.7 [9.2 13.1]	364	10.7 [9.1 12.8]	256	10.8 [9.2 13.4]	0.525
PaCO ₂	kPa	412	6.2 [5.3 7.6]	223	6.2 [5.3 7.5]	189	6.3 [5.4 7.6]	0.591
Base excess		620	-0.3 [-2.6 2.2]	364	0.2 [-2.2 2.5]	256	-0.8 [-3.1 1.6]	0.002
HCO ₃ ⁻	mmol/L	619	24.5 [22.5 26.7]	363	24.9 [22.9 27.0]	256	23.9 [21.9 26.0]	0.001
Lactate	mmol/L	594	1.2 [1.0 1.6]	348	1.1 [0.9 1.5]	246	1.4 [1.1 1.8]	0.000
SOFA								
SOFA score		419	9.0 [7.0 11.0]	247	8.0 [6.0 11.0]	172	9.0 [8.0 12.0]	0.000
SOFA Respiratory		616	3.0 [3.0 3.0]	360	3.0 [2.0 3.0]	256	3.0 [3.0 4.0]	0.000
SOFA Nervous		498	2.5 [0.0 4.0]	302	0.0 [0.0 4.0]	196	4.0 [0.0 4.0]	0.079
SOFA Cardiovascular		569	3.0 [3.0 4.0]	329	3.0 [3.0 3.0]	240	3.0 [3.0 4.0]	0.000
SOFA Liver		579	0.0 [0.0 0.0]	336	0.0 [0.0 0.0]	243	0.0 [0.0 0.0]	0.621
SOFA Coagulation		609	0.0 [0.0 0.0]	356	0.0 [0.0 0.0]	253	0.0 [0.0 0.0]	0.004
SOFA Kidneys		619	0.0 [0.0 1.0]	363	0.0 [0.0 1.0]	256	0.0 [0.0 1.0]	0.014
FBC								
Haemoglobin	g/dL	609	114.0 [93.0 128.0]	356	115.0 [95.5 128.0]	253	114.0 [86.0 129.0]	0.537
Haematocrit		302	0.4 [0.3 0.4]	169	0.4 [0.3 0.4]	133	0.4 [0.3 0.4]	0.043
White blood cell count	x10 ⁹ /L	609	9.6 [7.0 13.1]	356	9.4 [6.9 12.6]	253	9.9 [7.3 13.6]	0.204
Neutrophils	x10 ⁹ /L	608	8.1 [5.7 11.3]	356	7.5 [5.3 10.7]	252	8.6 [6.2 12.3]	0.010
Monocytes	x10 ⁹ /L	604	0.4 [0.3 0.7]	356	0.5 [0.3 0.7]	248	0.4 [0.2 0.7]	0.002
Lymphocytes	x10 ⁹ /L	605	0.8 [0.5 1.2]	356	0.9 [0.6 1.3]	249	0.7 [0.5 1.1]	0.000
Basophils	x10 ⁹ /L	488	0.0 [0.0 0.1]	282	0.0 [0.0 0.1]	206	0.0 [0.0 0.0]	0.001
Eosinophils	x10 ⁹ /L	483	0.0 [0.0 0.1]	287	0.1 [0.0 0.1]	196	0.0 [0.0 0.1]	0.000
Coag								
Platelet Count	μmol/L	609	247.0 [186.8 321.0]	356	264.0 [199.0 338.0]	253	228.0 [170.8 304.3]	0.000
APTT	U/L	389	32.0 [28.3 37.1]	210	32.3 [28.7 37.4]	179	32.0 [28.0 36.9]	0.392
PT	U/L	387	13.8 [12.4 15.2]	210	13.9 [12.5 15.1]	177	13.8 [12.1 15.4]	0.991
INR	U/L	211	1.1 [1.1 1.2]	115	1.1 [1.1 1.2]	96	1.1 [1.1 1.2]	0.724
Fibrinogen	U/L	401	6.8 [5.6 8.1]	247	6.8 [5.7 8.0]	154	6.7 [5.5 8.2]	0.468
D-dimer	U/L	388	2605.5 [991.0 7647.5]	223	2270.0 [904.3 5465.0]	165	3285.0 [1254.8 15579.8]	0.002
Electrolytes								
Blood Urea Nitrogen (BUN)	mmol/L	488	7.4 [4.9 11.7]	276	6.8 [4.7 10.4]	212	8.3 [5.6 13.3]	0.000
Creatinine	μmol/L	611	88.0 [66.0 139.8]	357	82.0 [63.0 126.0]	254	98.0 [71.0 152.0]	0.000
Sodium	mmol/L	611	139.0 [136.0 142.0]	358	139.0 [136.0 142.0]	253	138.0 [135.0 141.3]	0.062
Potassium	mmol/L	610	4.4 [4.0 4.8]	357	4.4 [4.0 4.8]	253	4.4 [4.1 4.8]	0.629
Liver								
Bilirubin	μmol/L	579	10.0 [7.0 15.0]	336	10.0 [7.0 14.0]	243	10.0 [7.0 15.0]	0.085
Alkaline Phosphatase	U/L	591	77.0 [58.3 113.0]	343	76.0 [53.3 116.8]	248	78.5 [62.0 108.0]	0.449
AST	U/L	97	59.0 [38.5 85.0]	50	53.0 [37.0 63.0]	47	70.0 [41.8 94.6]	0.022
ALT	U/L	584	37.0 [24.0 59.0]	339	37.0 [23.3 61.8]	245	37.0 [24.0 56.3]	0.757
Inflammation								
LDH (Lactate dehydrogenase)	U/L	192	649.0 [459.5 923.3]	111	618.0 [599.5 838.3]	81	683.0 [506.3 977.3]	0.102
Ferritin	ng/mL	288	1218.5 [693.5 2333.0]	175	1144.0 [676.5 2066.8]	113	1410.0 [714.8 2927.8]	0.021
CRP	mg/L	586	216.4 [135.0 311.7]	351	201.0 [117.6 298.0]	235	242.4 [159.3 327.9]	0.000
Procalcitonin	ug/L	118	0.7 [0.3 2.1]	85	0.5 [0.3 1.2]	33	1.6 [0.6 5.2]	0.000
Cardiac								
Creatinine Kinase	U/L	242	219.0 [85.0 638.0]	134	209.5 [85.0 579.0]	108	221.5 [84.5 639.0]	0.822
High sensitivity Troponin	ng/L	249	21.8 [10.9 60.3]	148	15.7 [9.0 40.5]	101	29.7 [13.2 94.0]	0.001
NT Pro BNP	pg/ml	58	537.5 [165.0 1478.0]	37	349.0 [139.0 823.5]	21	857.0 [565.0 3416.8]	0.005
Fluid								
Cumulative Fluid balance	L	574	332.1 [-224.0 1031.8]	339	272.0 [-267.0 940.0]	235	384.0 [-190.3 1312.0]	0.087
Adjunctive interventions								
Was patient transferred in?		623	159 (25.5%)	366	105 (28.7%)	257	54 (21%)	0.030
Tracheostomy		506	145 (28.7%)	306	122 (39.9%)	200	23 (11.5%)	0.000
PEEP>10		612	450 (73.5%)	360	232 (64.4%)	252	218 (86.5%)	0.000
Neuro-muscular blockade		607	427 (70.3%)	355	216 (60.8%)	252	211 (83.7%)	0.000
Prone positioning		541	268 (49.5%)	329	130 (39.5%)	212	138 (65.1%)	0.000
Inhaled nitric oxide		511	73 (14.3%)	310	29 (9.35%)	201	44 (21.9%)	0.000
Inhaled prostacyclin		511	54 (10.6%)	310	30 (9.68%)	201	24 (11.9%)	0.618
Bronchoscopy		511	49 (9.59%)	310	33 (10.6%)	201	16 (7.96%)	0.203
Renal replacement therapy		545	206 (37.8%)	323	90 (27.9%)	222	116 (52.3%)	0.000
Diuretics		588	442 (75.2%)	349	258 (73.9%)	239	184 (77%)	0.765
Corticosteroids		572	302 (52.8%)	343	175 (51%)	229	127 (55.5%)	0.694
Therapeutic heparin		428	55 (12.9%)	254	30 (11.8%)	174	25 (14.4%)	0.507
Antibiotics		303	211 (69.6%)	169	108 (63.9%)	134	103 (76.9%)	0.006
Prone								
No of proning episodes		268	1.0 [1.0 2.0]	130	1.0 [1.0 2.0]	138	1.0 [1.0 2.0]	0.850
mech vent prior first prone	days	268	3.0 [1.5 6.0]	130	3.0 [1.0 6.0]	138	4.0 [2.0 7.0]	0.141
durationn of first prone	days	268	2.0 [1.0 4.0]	130	2.0 [1.0 4.0]	138	2.0 [1.0 3.0]	0.548
responders to proning		266	118 (44.4%)	129	83 (64.3%)	137	35 (25.5%)	0.005
Tracheostomy								
mech vent prior to tracheostomy	days	145	13.0 [9.0 18.0]	122	14.0 [10.0 18.0]	23	13.0 [4.0 18.8]	0.127
durationn of tracheostomy	days	145	14.0 [6.0 21.3]	122	15.0 [7.0 22.0]	23	6.0 [2.3 12.8]	0.001

Table S14 - Time series mixed model ANOVA according to ICU outcome.

label	N	p-values		
		Dead vs Alive	parameter over time	interaction
PaO ₂ / FiO ₂	468	0.000	0.000	0.000
Dynamic Compliance	337	0.000	0.000	0.000
Respiratory rate	454	0.070	0.001	0.580
FiO ₂ (%)	499	0.000	0.000	0.000
Tidal Volume per Kg	346	0.957	0.221	0.447
Tidal Volume	429	0.370	0.249	0.558
Minute ventilation	400	0.052	0.000	0.227
Peak pressure	422	0.000	0.000	0.000
PEEP	386	0.000	0.001	0.154
Dynamic delta pressure (peakP-peep)	124	0.001	0.058	0.009
Mean airway pressure	255	0.000	0.000	0.000
I:E ratio	93	0.050	0.552	0.261
Pressure support	165	0.022	0.034	0.042
Oxygen saturation	413	0.000	0.132	0.003
pH	483	0.000	0.000	0.000
PaO ₂	480	0.422	0.319	0.121
PaCO ₂	309	0.001	0.103	0.000
Base excess	474	0.000	0.000	0.280
HCO ₃ ⁻	475	0.000	0.000	0.257
Lactate	447	0.000	0.277	0.027
Oxygenation Index	236	0.000	0.000	0.000
Ventilatory Ratio	167	0.040	0.426	0.017
Mean arterial pressure (lowest)	382	0.000	0.000	0.000
Liver-Bilirubin	167	0.017	0.103	0.248
Daily fluid balance	470	0.000	0.000	0.305
Cumulative fluid balance	470	0.000	0.005	0.000
SOFA Score	191	0.000	0.000	0.000
Non-Respiratory SOFA	223	0.000	0.000	0.000
Glucose	461	0.026	0.061	0.299
BUN	378	0.000	0.008	0.000
Creatinine	516	0.000	0.121	0.000
Sodium	519	0.518	0.000	0.387
Potassium	514	0.000	0.723	0.005
Bilirubin	400	0.003	0.000	0.000
Alkaline Phosphatase	438	0.982	0.000	0.353
AST	55	0.988	0.517	0.559
ALT	418	0.113	0.000	0.259
Creatinine Kinase	127	0.534	0.415	0.509
LDH	66	0.583	0.001	0.306
Haemoglobin	511	0.001	0.094	0.070
WBC	509	0.015	0.002	0.013
RBC	411	0.203	0.482	0.529
Platelet Count	507	0.000	0.000	0.001
Haematocrit	249	0.777	0.000	0.001
Neutrophils	507	0.000	0.014	0.002
Monocytes	505	0.000	0.000	0.113
Lymphocytes	505	0.001	0.000	0.008
Basophils	357	0.019	0.003	0.443
Eosinophils	382	0.000	0.000	0.632
APTT	255	0.011	0.216	0.001
PT	260	0.538	0.515	0.553
INR	163	0.834	0.877	0.659
Fibrinogen	137	0.532	0.008	0.592
Ferritin	75	0.085	0.158	0.093
D-dimer	147	0.000	0.931	0.706
CRP	456	0.000	0.000	0.007
High sensitivity Troponin	62	0.143	0.082	0.222

Table S15- Uni- and multi-variate model analysis of factors associated with ICU mortality.

FieldLabel	median [IQR]	Univariate			Multivariate		
		Odds ratio	95% CI	P Value	Odds ratio	95% CI	P Value
Age (per decade)		2.061	1.726 - 2.461	0.000	2.106	1.692 - 2.620	0.000
Male		1.622	1.074 - 2.450	0.022	2.467	1.393 - 4.367	0.002
BMI	28.08 [24.90 32.70]	0.821	0.699 - 0.965	0.017	0.897	0.685 - 1.175	0.430
Weight	84.00 [75.00 95.00]	0.787	0.674 - 0.918	0.002	0.845	0.644 - 1.110	0.226
Height	173.00 [165.00 178.00]	0.910	0.773 - 1.071	0.255			
symptoms days	8.00 [6.00 12.00]	0.901	0.764 - 1.064	0.219			
Hypertension		1.378	0.977 - 1.944	0.068	1.081	0.689 - 1.695	0.734
COPD		1.589	0.793 - 3.186	0.192			
Diabetes mellitus		1.170	0.802 - 1.707	0.415			
CKD		2.426	0.940 - 6.259	0.067	1.594	0.494 - 5.143	0.435
Solid tumour		1.391	0.593 - 3.265	0.448			
Oxygen saturation	95.00 [93.00 98.00]	0.833	0.711 - 0.976	0.024	1.061	0.859 - 1.310	0.585
pH	7.36 [7.30 7.42]	0.801	0.688 - 0.933	0.004	1.081	0.787 - 1.486	0.629
PaCO_2	6.20 [5.30 7.58]	1.153	0.984 - 1.352	0.079	1.482	1.071 - 2.050	0.018
HCO^-3	24.50 [22.50 26.70]	0.780	0.669 - 0.910	0.002	0.808	0.635 - 1.029	0.084
Lactate	1.20 [1.00 1.60]	1.579	1.340 - 1.862	0.000	1.586	1.262 - 1.994	0.000
Peak pressure	26.00 [23.00 30.00]	1.290	1.102 - 1.509	0.002	1.079	0.817 - 1.426	0.591
PEEP	10.00 [8.00 12.00]	1.397	1.169 - 1.668	0.000	1.142	0.888 - 1.470	0.301
Minute ventilation	8.49 [6.85 10.37]	0.960	0.826 - 1.116	0.597			
Dynamic Comp	31.44 [24.26 40.15]	0.846	0.724 - 0.989	0.036	0.770	0.595 - 0.997	0.047
Oxygenation Index	8.11 [5.10 12.59]	1.304	1.104 - 1.540	0.002	1.135	0.841 - 1.533	0.407
Cum fluid balance	332.10 [-224.00 1031.80]	1.122	0.963 - 1.308	0.141			
Neutrophils	8.05 [5.71 11.30]	1.233	1.058 - 1.437	0.007	1.162	0.928 - 1.454	0.190
Monocytes	0.41 [0.30 0.70]	0.791	0.680 - 0.919	0.002	0.807	0.651 - 1.001	0.051
Eosinophils	0.00 [0.00 0.10]	0.375	0.258 - 0.544	0.000	0.417	0.253 - 0.686	0.001
APTT	32.00 [28.28 37.10]	1.043	0.884 - 1.231	0.615			
PT	13.80 [12.40 15.20]	1.031	0.872 - 1.220	0.719			
Fibrinogen	6.80 [5.60 8.10]	1.017	0.864 - 1.197	0.838			
D-dimer	2605.50 [991.00 7647.50]	1.247	1.057 - 1.471	0.009	0.986	0.791 - 1.228	0.897
BUN	7.40 [4.90 11.70]	1.426	1.217 - 1.670	0.000	1.048	0.799 - 1.376	0.733
Sodium	139.00 [136.00 142.00]	0.873	0.749 - 1.018	0.083	0.922	0.753 - 1.129	0.431
Potassium	4.40 [4.00 4.80]	1.058	0.908 - 1.233	0.469			
ALP	77.00 [58.25 113.00]	1.034	0.890 - 1.201	0.662			
ALT	37.00 [24.00 59.00]	0.962	0.828 - 1.118	0.612			
CRP	216.40 [135.00 311.70]	1.327	1.135 - 1.551	0.000	1.089	0.883 - 1.343	0.428
SOFA Respiratory		1.406	1.155 - 1.712	0.001	1.279	0.881 - 1.857	0.196
SOFA Nervous		1.108	1.016 - 1.210	0.021	1.247	1.007 - 1.543	0.043
SOFA Cardio		1.254	1.073 - 1.466	0.004	1.201	0.945 - 1.527	0.135
SOFA Liver		1.102	0.805 - 1.508	0.546			
SOFA Coagulation		1.607	1.148 - 2.252	0.006	2.108	1.314 - 3.383	0.002
SOFA Kidneys		1.217	1.039 - 1.425	0.015	1.353	0.970 - 1.886	0.075
SOFA score		1.191	1.108 - 1.280	0.000	0.817	0.665 - 1.002	0.053

Table S16 - Cardiac arrest and end of life decisions

	All			Discharged			Died		
	N	count	%	N	count	%	N	count	%
Was life sustaining therapy withdrawn prior to death	183	84	45.9	56	2	3.6	127	82	64.6
COVID death	184	183	99.5	0	0		184	183	99.5
Did the patient have a cardiac arrest during their admission	234	20	8.5	121	8	6.6	113	12	10.6

Table S17 - Missing values for each parameter

Site	All	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q
N	623	1	18	35	49	19	36	57	34	3	64	54	4	9	31	2	173	
% of Missing Data																		
PaO ₂ / FIO ₂	6.1	1.9	5.5	2.6	7.9	6.6	1.5	10.1	4.2	22.3	0.0	1.1	6.1	0.0	0.0	4.9	0.0	4.6
Oxygen saturation	21.4	0.0	6.9	0.0	1.0	100.0	100.0	100.0	0.0	2.1	0.0	1.1	0.2	0.0	0.0	0.0	0.0	0.1
pH	4.6	1.9	4.4	1.4	2.4	6.1	1.4	9.8	4.2	12.5	0.0	1.3	6.5	0.0	0.0	2.9	0.0	4.1
PaCO ₂	43.7	1.9	4.4	100.0	2.4	6.1	1.4	9.8	3.9	12.5	0.0	1.3	6.3	0.0	0.0	2.9	0.0	100.0
Base excess	5.5	1.9	4.7	1.8	2.5	17.5	2.4	11.6	4.2	14.0	0.0	2.0	6.8	0.0	0.0	2.9	0.0	4.2
HCO ₃ ⁻	5.2	1.9	4.4	1.9	2.4	13.0	1.5	10.4	4.5	12.5	0.0	1.4	6.5	0.0	0.0	2.9	0.0	4.6
Lactate	9.4	100.0	4.4	3.1	2.4	6.1	1.4	9.8	5.1	12.5	0.0	1.4	7.0	0.0	0.0	89.8	0.0	4.7
Peak pressure	12.8	3.8	12.0	14.2	11.9	7.2	6.6	4.0	10.8	17.0	8.0	4.1	6.1	0.0	0.7	10.2	4.8	20.8
PEEP	14.6	1.9	16.0	20.1	9.3	0.3	2.2	0.4	6.0	17.8	0.0	1.7	4.0	0.0	0.7	3.8	4.8	29.7
Mean airway pressure	41.2	24.5	99.6	22.0	14.1	82.0	28.0	11.8	96.1	20.4	32.0	99.5	97.5	0.0	22.1	58.3	100.0	31.9
Tidal Volume per Kg	30.1	7.5	50.9	14.0	27.6	8.3	22.3	89.2	6.0	14.2	0.0	14.9	36.9	61.3	97.1	47.2	100.0	20.8
Respiratory rate	11.6	56.6	10.5	12.8	34.3	0.0	0.0	0.1	0.0	9.8	0.0	0.3	0.2	0.0	0.0	4.9	0.0	20.5
Minute ventilation	15.6	62.3	33.8	14.5	36.5	7.8	6.2	2.5	2.4	16.4	0.0	3.6	3.8	0.0	0.7	21.2	4.8	21.6
Dynamic Compliance	19.1	9.4	37.1	20.5	13.8	12.7	9.1	5.5	16.0	19.8	0.0	6.1	4.5	3.2	1.4	25.6	4.8	30.9
Oxygenation Index	42.8	24.5	99.6	22.3	16.0	82.0	29.1	20.1	96.1	25.1	32.0	99.5	97.5	0.0	22.1	59.2	100.0	32.3
Ventilatory Ratio	65.6	62.3	53.8	100.0	48.3	14.4	23.2	89.6	8.7	19.5	0.0	15.9	39.4	61.3	97.1	48.3	100.0	100.0
SOFA Score	47.0	96.2	21.1	21.9	17.2	65.1	53.6	68.1	57.8	81.0	84.0	76.1	54.7	3.2	47.1	79.7	47.6	31.5
Non-Respiratory SOFA	43.5	96.2	18.2	18.2	8.1	62.9	51.9	59.5	56.3	77.7	84.0	76.0	51.8	3.2	47.1	79.2	47.6	28.5
Cumulative fluid balance	11.4	100.0	5.1	4.0	7.1	2.8	4.2	28.4	0.0	10.4	4.0	2.5	2.0	0.0	1.4	99.3	0.0	3.8
WBC	5.4	3.8	1.8	5.5	1.3	7.8	4.2	5.4	3.3	6.6	8.0	2.4	3.8	0.0	5.0	5.7	23.8	7.3
Neutrophils	5.8	3.8	2.5	5.5	1.3	8.9	6.2	6.1	3.3	6.6	8.0	2.5	4.9	3.2	5.7	5.5	23.8	7.3
Monocytes	6.0	3.8	2.5	6.5	1.3	8.9	6.2	6.2	3.3	6.6	8.0	4.1	4.9	3.2	5.7	5.7	23.8	7.4
Lymphocytes	5.9	3.8	2.5	5.5	1.3	8.9	6.2	6.2	3.6	6.6	8.0	4.2	4.9	3.2	5.7	5.5	23.8	7.4
Platelet Count	5.6	3.8	1.8	5.5	1.3	9.1	3.9	5.1	4.5	6.6	8.0	2.2	3.6	0.0	6.4	5.7	23.8	7.6
APTT	49.8	9.4	2.5	100.0	2.8	10.0	5.7	6.1	13.9	13.1	8.0	8.5	52.7	16.1	42.1	44.6	81.0	100.0
PT	49.8	9.4	2.9	100.0	2.9	10.0	5.5	6.9	13.9	12.4	8.0	6.6	54.3	6.5	43.6	44.6	81.0	100.0
Fibrinogen	50.1	39.6	16.0	23.0	10.3	100.0	100.0	100.0	99.1	33.6	52.0	21.5	55.0	16.1	70.0	56.3	85.7	37.7
D-dimer	48.2	100.0	71.6	63.4	17.4	10.8	10.7	11.3	20.8	57.7	60.0	49.5	73.4	3.2	30.7	92.7	95.2	63.1
BUN	25.8	100.0	19.3	10.2	100.0	8.3	4.2	4.9	3.9	100.0	8.0	7.4	2.7	0.0	10.0	99.6	4.8	11.1
Creatinine	5.6	3.8	6.2	6.4	3.3	8.0	4.2	4.9	4.2	5.6	8.0	3.8	2.7	0.0	6.4	5.7	4.8	7.0
Sodium	4.8	3.8	6.9	6.5	1.4	5.3	0.8	2.5	3.6	5.6	8.0	3.5	3.2	0.0	2.9	5.7	4.8	7.0
Potassium	5.3	3.8	6.2	7.0	3.6	5.3	0.8	2.5	4.2	6.0	8.0	3.9	2.9	3.2	2.9	6.2	4.8	7.6
Bilirubin	15.4	11.3	6.2	14.0	1.7	19.4	4.6	20.8	8.1	6.0	12.0	2.8	36.7	3.2	46.4	60.0	42.9	13.9
Alkaline Phosphatase	10.7	11.3	10.2	8.6	1.7	8.0	4.2	4.9	11.1	5.8	12.0	1.9	32.4	3.2	27.1	60.7	42.9	8.1
ALT	12.5	11.3	5.8	11.4	1.7	8.9	9.1	6.2	6.6	6.0	12.0	2.5	38.1	0.0	46.4	60.3	52.4	10.2
LDH	80.3	98.1	95.3	97.2	11.0	100.0	100.0	99.2	17.5	50.3	96.0	51.3	74.3	6.5	98.6	88.1	95.2	94.9
Ferritin	63.2	98.1	74.9	56.9	18.3	100.0	100.0	100.0	19.3	58.0	68.0	44.4	71.6	32.3	32.1	79.7	100.0	56.1
CRP	10.3	3.8	19.6	6.4	1.8	7.5	5.3	4.6	13.3	5.8	16.0	2.0	74.3	3.2	4.3	6.2	95.2	7.6
Creatinine Kinase	71.0	98.1	99.3	100.0	7.7	82.8	40.4	70.7	13.6	25.8	48.0	7.8	99.3	32.3	100.0	87.4	95.2	100.0
High sensitivity Troponin	64.2	100.0	78.9	55.2	6.8	100.0	100.0	100.0	92.5	47.3	52.0	43.6	73.2	29.0	42.9	88.3	100.0	55.0
NT Pro BNP	97.0	100.0	78.2	96.8	99.6	100.0	100.0	100.0	97.3	88.9	100.0	99.8	100.0	96.8	97.9	97.8	95.2	96.4

Figure S1 – Time-series comparison between admission severity groups




Figure S2 – Site variation of application of interventions




Figure S3 – Time series comparison between outcome groups

